Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients

Bone Marrow Transplantation

Volumn 41, Issue 10, 2008, Pages 873-879

  Gerna, G ^a   Lilleri, D ^a   Caldera, D ^a   Furione, M ^a   Zenone Bragotti, L ^a   Alessandrino, E P ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; FOSCARNET; GANCICLOVIR; METHOTREXATE; METHYLPREDNISOLONE; STEROID; THYMOCYTE ANTIBODY; VIRUS DNA;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN DETECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; FEMALE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; STANDARDIZATION; STOMACH BIOPSY; STOMACH DISEASE; VALIDATION STUDY; VIREMIA; VIRUS DETECTION; VIRUS REPLICATION;

ADULT; AGED; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CD4-CD8 RATIO; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED;

EID: 44449090056     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705986     Document Type: Article

References (26)

1. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 1996; 88: 4063-4071.
2. Nguyen Q, Champlin R, Giralt S, Rolston K, Raad I, Jacobson K et al Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999; 28: 618-623.
3. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358-1364.
4. Locatelli F, Percivalle E, Comoli P, Maccario R, Zecca M, Giorgiani G et al. Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone marrow transplantation: Role of early antiviral treatment for HCMV antigenaemia on patients outcome. Br J Hematol 1994; 88: 64-71.
5. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
6. Ljungman P, Aschan J, Lewensohn-Fuchs I. Carlens S. Larsson K, Lonnqvist B et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66: 1330-1334.
7. Enright H, Haake R, Weisdorf D, Ramsay N, McGlave P, Kersey J et al Cytomegalovirus pneumonia after bone marrow transplantation: Risk factors and response to therapy. Transplantation 1993; 55: 1339-1346.
8. Gerna G, Lilleri D, Baldanti F, Torsellini M, Giorgiani G, Zecca M et al. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: A prospective, randomized, open-label trial. Blood 2003; 101: 5053-5060.
9. Lilleri D, Baldanti F, Gatti M, Rovida F, Dossena L, De Grazia S et al. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy of human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J Med Virol 2004; 73: 412-418.
10. Gerna G, Lilleri D. Monitoring transplant patients for human cytomegalovirus: Diagnostic update. Herpes 2006; 13: 4-11.
11. Lilleri D, Gerna G, Furione M, Bernardo ME, Giorgiani G, Telli S et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of pre-emptively treated children and young adults receiving haematopoietic stem cell transplantation as compared to qualitative pp65-antigenemia. Blood 2007; 10: 2757-2760.
12. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalo-virus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
13. Salvaneschi L, Perotti C, Zecca M, Bernuzzi S, Viarengo G, Giorgiani G et al. Extracorporeal photochemotherapy for treatment of acute and chronic GvHD in childhood. Transfusion 2001; 41: 1299-1305.
14. Gerna G, Revello MG, Percivalle E, Torsellini M, A 6-h microneutralization assay for human cytomegalovirus antibody by using monoclonal antibodies. Serodiagn Immunother Infect Dis 1990; 4 243-247.
15. Gerna G, Vitulo P, Rovida F, Lilleri D, Pellegrini C, Oggionni T et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol 2006; 78: 408-416.
16. Boom R, Sol CJA, Salimans MMM. Jansen CL. Wertheim-van Dillen PME, van der Nordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495-503.
17. Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30: 1232-1237.
18. Gerna G, Percivalle E, Torsellini M, Revello MG. Standardization or the human cytomegalovirus antigenemia assay by means of in vivo generated pp65-positive peripheral blood polymorphonuclear leukocytes. J Clin Microbiol 1998; 36: 3585-3589.
19. Lozza L, Lilleri D, Percivalle E, Fornara C, Comolli G, Revello MG et al. Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4 + and CD8 + T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur J Immunol 2005; 35: 1795-1804.
20. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
21. Klein JP, Rizzo JD, Zhang M-J, Keiding N. Statistical methods for analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis. Bone Marrow Transplant 2001: 28 909-915.
22. Gerna G, Lilleri D, Zecca M, Alessandrino EP, Baldanti F, Revello MG et al. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegaloviras infection in allogeneic hematopoietic stem cell transplant recipients. Haematalogica 2005; 90: 526-533.
23. Gerna G, Sarasini A, Lilleri D, Percivalle E, Torsellini M, Baldanti F et al. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J Infect Dis 2003; 188: 1639-1647.
24. Verkruyse LA, Storch GA, Devine SM, Dipersio JF, Vij R. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load>or - 10 000 copies ml: A safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant 2006; 37 51-56.
25. Lilleri D, Gerna G, Fornara C, Lozza L, Maccario R, Locatelli F. Prospective simultaneous quantificaiion of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 2006; 108: 1406-1412.
26. Gerna G, Zavattoni M, Baldanti F, Sarasini A, Chezzi L, Grossi P et al. Human cytomegalovirus (HCMV) leuko DNAemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection. Transplantation 1998; 65: 1378-1385.